康美药业
(600518)
| 流通市值：183.84亿 | | | 总市值：183.92亿 |
| 流通股本：138.22亿 | | | 总股本：138.29亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 2,290,489,817.26 | 1,079,786,637.44 | 5,252,215,058.26 | 3,959,603,514.66 |
| 营业总成本 | 2,341,857,641.18 | 1,098,903,388.14 | 5,360,814,274.25 | 4,028,487,323.58 |
| 其他经营收益 | | | | |
| 营业利润 | 35,410,359.68 | -13,331,236.09 | 35,011,099.83 | 31,731,784.63 |
| 利润总额 | 40,999,009.3 | -14,007,250.42 | 43,115,914.49 | 30,593,043.45 |
| 净利润 | 37,367,319.7 | -15,980,697.84 | 12,429,169.97 | 15,091,123.76 |
| 每股收益 | | | | |
| 其他综合收益 | -25,018.7 | -15,805.99 | -80,909.46 | -69,577.23 |
| 综合收益总额 | 37,342,301 | -15,996,503.83 | 12,348,260.51 | 15,021,546.53 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 6,660,033,438.49 | 6,803,467,737.62 | 6,651,428,280.98 | 7,029,301,322.75 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,407,943,420.97 | 6,503,818,479.48 | 6,568,317,706.52 | 6,653,633,185.22 |
| 资产总计 | 13,067,976,859.46 | 13,307,286,217.1 | 13,219,745,987.5 | 13,682,934,507.97 |
| 流动负债: | | | | |
| 流动负债合计 | 5,097,140,814.55 | 5,377,618,653.14 | 5,265,890,988.78 | 5,811,410,908.78 |
| 非流动负债: | | | | |
| 非流动负债合计 | 608,415,416.86 | 620,163,661.95 | 628,447,463.74 | 646,840,432.81 |
| 负债合计 | 5,705,556,231.41 | 5,997,782,315.09 | 5,894,338,452.52 | 6,458,251,341.59 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 7,325,686,836.82 | 7,273,519,463.33 | 7,290,006,280.85 | 7,186,774,270 |
| 股东权益合计 | 7,362,420,628.05 | 7,309,503,902.01 | 7,325,407,534.98 | 7,224,683,166.38 |
| 负债和股东权益合计 | 13,067,976,859.46 | 13,307,286,217.1 | 13,219,745,987.5 | 13,682,934,507.97 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,584,320,981.13 | 1,117,376,663.23 | 5,583,275,223.81 | 4,080,112,731.76 |
| 经营活动现金流出小计 | 2,548,268,137.62 | 1,172,132,012.49 | 5,471,928,595.94 | 3,942,270,231.96 |
| 经营活动产生的现金流量净额 | 36,052,843.51 | -54,755,349.26 | 111,346,627.87 | 137,842,499.8 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,632,998.79 | 2,149,942.5 | 39,788,889.32 | 20,080,726.32 |
| 投资活动现金流出小计 | 29,770,624.32 | 15,701,885.89 | 217,059,298.38 | 74,116,991.9 |
| 投资活动产生的现金流量净额 | -27,137,625.53 | -13,551,943.39 | -177,270,409.06 | -54,036,265.58 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 92,461,627.58 | 42,312,265.95 | 377,320,528.09 | 188,493,185.99 |
| 筹资活动现金流出小计 | 17,116,213.87 | 8,587,100.3 | 88,070,284.94 | 70,828,841.64 |
| 筹资活动产生的现金流量净额 | 75,345,413.71 | 33,725,165.65 | 289,250,243.15 | 117,664,344.35 |
| 汇率变动对现金及现金等价物的影响 | -28,399.8 | -16,599.73 | -13,988.28 | -6,353.22 |
| 现金及现金等价物净增加额 | 84,232,231.89 | -34,598,726.73 | 223,312,473.68 | 201,464,225.35 |
| 期末现金及现金等价物余额 | 1,150,524,577.34 | 1,031,693,618.72 | 1,066,292,345.45 | 1,044,444,097.12 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 84,232,231.89 | - | 223,312,473.68 | - |